Report on Clopidogrel in China, 2018-2022” report has been
added to ResearchAndMarkets.com’s offering.
This research predicts that with the rising aging population, the change
of lifestyle and the increasing incidence of cerebral stroke, myocardial
infarction and peripheral arterial thromboembolism, the demand for
Clopidogrel in the Chinese market will continue to increase.
Clopidogrel was approved to be sold on the market by the FDA in 1997.
The drug was jointly researched and developed by Bristol-Myers Squibb
and Sanofi. Prior to the patent expiration in 2012, Plavix was ranked
after Lipitor for many years and was the second best-selling drug in the
world. After the patent expired, a global wave of biosimilar boomed.
For years, Clopidogrel has been ranking first in China’s antithrombotic
drug market, with sales revenue exceeding CNY 2 billion in 2017.
According to market research, Clopidogrel in the Chinese market is
dominated by four companies, namely, Sanofi (Hangzhou) Pharmaceutical
Co., Ltd. (Trade Name: Plavix), Shenzhen Salubris Pharmaceutical Co.,
Ltd. (Trade Name: Taijia), Lepu Pharmaceutical Co., Ltd. (Trade Name:
Shuai Tai) and Sanofi (Trade Name: Plavix).
According to the sales in 2017, Sanofi (Hangzhou) secured a market share
of 52%, ranking first in the Chinese market for a long time.
Key Topics Covered
1 Relevant Concepts of Clopidogrel
2 Market Overview of Clopidogrel in China
3 Investigation of Clopidogrel’s Sales in China, 2013-2017
4 Market Share of Clopidogrel Manufacturers in China, 2013-2017
5 Clopidogrel in Different Dosage Forms, 2013-2017
6 Reference Sale Price of Clopidogrel in Chinese Market, 2017-2018
7 Major Clopidogrel Manufacturers in Chinese Market, 2013-2017
8 Prospects of Chinese Clopidogrel Market, 2018-2022
For more information about this report visit https://www.researchandmarkets.com/research/ftc7cl/clopidogrel?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005669/en/